Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 23 Apr 2024 07:00 CEST |
BenevolentAI | BenevolentAI Provides an Update on Its Business Priorities | 20103010 Biotechnology | Commercial operations |
| 17 Apr 2024 07:00 CEST |
BenevolentAI | BenevolentAI: Publication of the Revised Agenda for the 2024 AGM | 20103010 Biotechnology | General meeting / Board Meeting |
| 15 Apr 2024 07:00 CEST |
BenevolentAI | Proposed Changes to BenevolentAI’s Board Composition | 20103010 Biotechnology | Journal / appointments |
| 25 Mar 2024 07:00 CET |
BenevolentAI | BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers | 20103010 Biotechnology | Commercial operations |
| 20 Mar 2024 07:00 CET |
BenevolentAI | BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice | 20103010 Biotechnology | General meeting / Board Meeting |
| 14 Mar 2024 07:00 CET |
BenevolentAI | BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023 | 20103010 Biotechnology | Commercial operations |
| 24 Jan 2024 07:00 CET |
BenevolentAI | BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer | 20103010 Biotechnology | Journal / appointments |
| 28 Dec 2023 07:00 CET |
BenevolentAI | BenevolentAI:Shareholder Letter December 2023 | 20103010 Biotechnology | Other subject |
| 21 Sep 2023 07:01 CEST |
BenevolentAI | BenevolentAI: Interim Results for the Six Months Ended 30 June 2023 | 20103010 Biotechnology | Other subject |
| 21 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI: Directorate Change | 20103010 Biotechnology | Journal / appointments |
| 20 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI Signs Strategic Collaboration with Merck | 20103010 Biotechnology | Other subject |
| 18 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer | 20103010 Biotechnology | Journal / appointments |
| 15 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI Notice of Interim Results | 20103010 Biotechnology | Other subject |
| 11 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer | 20103010 Biotechnology | Journal / appointments |
| 31 Aug 2023 07:00 CEST |
BenevolentAI | BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis | 20103010 Biotechnology | New |
| 21 Jun 2023 07:00 CEST |
BenevolentAI | BenevolentAI: Board Change | 20103010 Biotechnology | Journal / appointments |
| 25 May 2023 07:00 CEST |
BenevolentAI | BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI | 20103010 Biotechnology | Other subject |
| 05 Apr 2023 07:00 CEST |
BenevolentAI | BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis | 20103010 Biotechnology | New |
| 24 Mar 2023 07:00 CET |
BenevolentAI | BenevolentAI Announces Publication of Convening Notice for AGM | 20103010 Biotechnology | General meeting / Board Meeting |
| 22 Mar 2023 07:00 CET |
BenevolentAI | BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani | 20103010 Biotechnology | New |
| 16 Mar 2023 07:00 CET |
BenevolentAI | BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 | 20103010 Biotechnology | Income |
| 06 Oct 2022 07:00 CEST |
BenevolentAI | BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca | 20103010 Biotechnology | New |
| 27 Sep 2022 14:55 CEST |
BenevolentAI | BenevolentAI Analyst / Investor Event | 20103010 Biotechnology | Meetings / events |
| 27 Sep 2022 07:00 CEST |
BenevolentAI | BenevolentAI Interim Results for the Six Months Ended 30 June 2022 | 20103010 Biotechnology | Income |